Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Mar 2021
ReviewPhysician well-being in allergy and immunology: Creating a culture of wellness.
There are 3 domains of physician wellness: (1) the culture of wellness, (2) efficiency of practice, and (3) physician resilience. The culture of wellness encompasses an organization's values, environment, and behaviors that foster compassion and growth in its physicians. ⋯ We need to address burnout at every level in health care, namely at health care organization and system levels, individual teams and offices, and at an individual level. In doing so, it becomes obvious that a lack of wellness (burnout) is a systems problem and not an individual's fault. We are all responsible for taking steps to change the culture to one of wellness. Working within our practices, organization, and allergy societies, we can change the culture to one of wellness.
-
Ann. Allergy Asthma Immunol. · Mar 2021
ReviewPhysician wellness in allergy and immunology: Personal resiliency.
Physician burnout and wellness are vital and current issues in medicine, including allergy and immunology. Resilience involves the ability to rebound from personal and professional adversities. Improving individual resilience can be used to combat many of these stresses. ⋯ As we address our own wellness and improve our resilience as physicians, the healthier we become and the better we can advocate for our patients and our specialty of allergy and immunology.
-
Ann. Allergy Asthma Immunol. · Feb 2021
Randomized Controlled Trial Multicenter StudyTezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Patients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved lung function, asthma control, and health-related quality of life vs placebo. ⋯ Tezepelumab treatment improved PROs vs placebo, as indicated by the higher proportion of ACQ-6 and AQLQ(S)+12 responders and improvements in symptom severity in the tezepelumab dose groups. These data further support the benefits of tezepelumab in patients with severe, uncontrolled asthma.